ライフサイエンスコーパス: daptomycin

1 s (hNP-1, vancomycin, gentamicin, or calcium-daptomycin).

2 derstanding of the action mode of A54145 and daptomycin.

3 lipopeptide (n = 35), that is, vancomycin or daptomycin.

4 ue of the cyclic lipodepsipeptide antibiotic daptomycin.

5 ly higher treatment failure in comparison to daptomycin.

6 antibiotics including the cyclic lipopeptide daptomycin.

7 e obtained by BMD for vancomycin but not for daptomycin.

8 rectly inhibits membrane permeabilization by daptomycin.

9 11-fold for vancomycin and +/- 1.16-fold for daptomycin.

10 o 2011 and who received either vancomycin or daptomycin.

11 on the cell envelope such as vancomycin and daptomycin.

12 range, 1.1-2.3 days]) prior to switching to daptomycin.

13 dentification and successful treatment using daptomycin.

14 correlated with increased susceptibility to daptomycin.

15 eptides (HDPs) prior to clinical exposure to daptomycin.

16 2) was from blood drawn after treatment with daptomycin.

17 ard therapy and relapse after treatment with daptomycin.

18 t to multiple drugs including vancomycin and daptomycin.

19 d increased susceptibility to the antibiotic daptomycin.

20 adaptation restores the in vivo activity of daptomycin.

21 uter leaflets of membranes are accessible to daptomycin.

22 ucturally related to the clinically approved daptomycin.

23 radual membrane depolarization observed with daptomycin.

24 log2 dilutions, and it was +/- 1.67-fold for daptomycin (10 results).

25 hort of critically ill patients treated with daptomycin 6-8 mg/kg/day for primarily Staphylococcus sp

26 ized to receive meropenem (1 g/8 hours) plus daptomycin (6 mg/kg/day) or ceftazidime (2 g/8 hours).

27 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%.

28 Daptomycin, a cyclic lipopeptide produced by Streptomyce

29 Daptomycin, a cyclic lipopeptide, is the only membrane-a

30 idated, particularly the question of whether daptomycin acts on the cell membrane, the cell wall, or

31 In mice treated with daptomycin, adjunctive cholestyramine therapy reduced th

32 isolates, follow-up blood culture data, and daptomycin administration data were available.

33 in, LL37, and alamethicin but not by CCCP or daptomycin, agents known to cause ion leakage.

34 ia also released phospholipid in response to daptomycin, Agr-triggered secretion of small cytolytic t

35 Daptomycin, although not currently approved for this ind

36 wed a 100-fold decrease in susceptibility to daptomycin, although this antibiotic was not used in the

37 The N-terminal domain of LiaX binds daptomycin and AMPs (such as human LL-37) and functions

38 hogen, evolves resistance to the lipopeptide daptomycin and AMPs by diverting the antibiotic away fro

39 istance to the membrane-targeting antibiotic daptomycin and demonstrates the conservation of NOS-deri

40 otic oxacillin, which slowed inactivation of daptomycin and enhanced bacterial killing.

41 usceptible-only breakpoint of <=4 mug/mL for daptomycin and enterococci was no longer appropriate.

42 lity Testing established new breakpoints for daptomycin and enterococci.

43 able cell membrane-targeting antimicrobials (daptomycin and telavancin), but also resulted in hypersu

44 h as the antibiotics vancomycin, bacitracin, daptomycin and the beta-lactam-containing penicillins, c

45 Vancomycin, daptomycin, and cloxacillin MIC was determined by E-test

46 s aureus and enterococci against vancomycin, daptomycin, and linezolid.

47 s to resistance to the last-line antibiotic, daptomycin, and simultaneously affects host innate immun

48 which cardiolipin may mediate resistance to daptomycin, and they provide new insights into the actio

49 aptomycin MICs of 3-4 microg/mL treated with daptomycin are more likely to have worse clinical outcom

50 Vancomycin and daptomycin are the first-line antibiotic choices for MRS

51 Linezolid and daptomycin are the primary treatment options for VRE-BSI

52 n the Vancomycin arm, and 11 (11.83%) in the Daptomycin arm (P = 0.43).

53 re at 30 days was significantly lower in the daptomycin arm compared to the vancomycin arm (20.0% vs

54 zed, 100 in the vancomycin arm and 50 in the daptomycin arm.

55 ore membrane binding, the molecular state of daptomycin as defined by CD is the same with or without

56 tyramine, which we show binds the antibiotic daptomycin, as an 'anti-antibiotic' to disable systemica

57 Daptomycin at 8 mg/kg every 48 hrs in critically ill pat

58 Daptomycin at 8 mg/kg intravenously over 30 mins.

59 Daptomycin at the dose of 6 mg/kg/day has been found to

60 eport our findings on the molecular state of daptomycin before and after its membrane-binding reactio

61 ncreased positive surface charge and reduced daptomycin binding.

62 icacies of a beta-lactam in combination with daptomycin (BL/D-C) and beta-lactam monotherapy (BL-M) i

63 hese proteins presumably is a key reason why daptomycin blocks cell wall synthesis.

64 Compared with standard-dose daptomycin, both medium-dose (HR, 0.78; 95% CI, .55-.90;

65 Compared to high-dose daptomycin, both standard-dose (hazard ratio [HR], 2.68;

66 therapy, suggesting that modification in the daptomycin breakpoint for enterococci should be consider

67 d Laboratory Standards Institute revised the daptomycin breakpoints for Enterococcus spp. twice in ra

68 terobacteriaceae and Pseudomonas aeruginosa, daptomycin breakpoints for Enterococcus spp., and ceftar

69 Wild-type S. aureus was killed rapidly by daptomycin, but Agr-defective mutants survived antibioti

70 d MX-2401 share structural similarities with daptomycin, but unlike daptomycin they do not target bac

71 structural basis for increased resistance to daptomycin by the adaptive mutation to LiaR (D191N) firs

72 We found that daptomycin causes a gradual decrease in membrane potenti

73 oved study of adult patients discharged with daptomycin, ceftaroline, ertapenem, and novel beta-lacta

74 Antibiotics included: daptomycin, ceftaroline, ertapenem, and the novel beta-l

75 (30.7% vs 10.8%) in patients with augmented daptomycin CL.

76 okinetic model were fitted to each subject's daptomycin concentration-time data and pharmacokinetic p

77 firmed progressive decreases in killing with daptomycin concentrations that simulate those attained i

78 l-angle x-ray scattering at sufficiently low daptomycin concentrations to determine that the molecule

79 Daptomycin concentrations were measured intensively over

80 Details of the mechanism of action of daptomycin continue to be elucidated, particularly the q

81 Under the same conditions, daptomycin continues to form oligomers; however, these o

82 Daptomycin continuous venovenous hemodialysis transmembr

83 The median daptomycin daily dose was 8.3 mg/kg (range, 6.4-10.7).

84 The lipopeptide antibiotic daptomycin (DAP) is a key drug against serious enterococ

85 The combination of daptomycin (DAP) plus ampicillin (AMP), ertapenem (ERT),

86 ggests the addition of a beta-lactam (BL) to daptomycin (DAP) results in synergistic in vitro activit

87 High-dose daptomycin (DAP) therapy failed in a neutropenic patient

88 The cyclic antimicrobial lipopeptide daptomycin (DAP) triggers the LiaFSR membrane stress res

89 andard antibiotic therapy with vancomycin or daptomycin did not result in significant improvement in

90 efects colocalize with fluorescently labeled daptomycin, DivIVA, and fluorescent reporters of peptido

91 There was no association between daptomycin dose and elevated creatinine kinase.

92 We included patients who received a daptomycin dose of >/=6 mg/kg for the treatment of VRE-B

93 Initial daptomycin dose of >/=8 mg/kg was not significantly asso

94 The best outcomes were associated with a daptomycin dose of >/=9 mg/kg compared to doses of <7 mg

95 Higher daptomycin doses (>/=9 mg/kg) were associated with lower

96 Higher daptomycin doses are advocated for select methicillin-re

97 Our results suggest that higher daptomycin doses need to be considered for VRE-BSI treat

98 A reappraisal of current daptomycin dosing recommendations is needed to improve t

99 ficient for the development of resistance to daptomycin during the treatment of vancomycin-resistant

100 However, the emergence of resistance to daptomycin during therapy threatens its usefulness.

101 In patients with MRSA bacteremia, daptomycin efficacy was not affected by GFR level and wa

102 embrane clearance was determined by dividing daptomycin effluent by serum concentrations and multiply

103 Simulations demonstrated 8 mg/kg daptomycin every 48 hrs would result in higher peak (88.

104 Daptomycin exhibits concentration-dependent activity vs

105 In the daptomycin-exposed group, daptomycin resistance of E. fa

106 f E. faecium isolated from rectal swabs from daptomycin-exposed patients was compared to a control gr

107 ic diversity in daptomycin resistance within daptomycin-exposed patients.

108 Daptomycin exposures were calculated using a published p

109 Significantly lower daptomycin exposures were observed despite comparable do

110 For enterococcal bacteremia, a daptomycin fAUC/MIC >27.43 was associated with 30-day su

111 Concerns regarding the efficacy of daptomycin for methicillin-resistant Staphylococcus aure

112 actice of switching early from vancomycin to daptomycin for the treatment of MRSAB when the vancomyci

113 pective cohort study comparing linezolid and daptomycin for the treatment of VRE-BSI among Veterans A

114 We included 112 patients treated with daptomycin for VRE-BSI and with evaluable clinical outco

115 or high-dose (>/=10 mg/kg total body weight) daptomycin for VRE-BSI.

116 sporus, is the active ingredient of Cubicin (daptomycin-for-injection), a first-in-class antibiotic a

117 in from Sigma, vancomycin from Novation, and daptomycin from Cubist.

118 imilar to the clinically approved antibiotic daptomycin from Streptomyces roseosporus, but has notabl

119 We hypothesized that the intravenous use of daptomycin generates off-target selection for resistance

120 y was observed, and bacteremia resolved with daptomycin, gentamicin, and/or linezolid treatment.

121 ven by a lower incidence of mortality in the daptomycin group (20% vs 9%; P = .046).

122 n the Vancomycin group and 11 (11.8%) in the Daptomycin group (P = 0.11).

123 the Vancomycin group and 10 (10.75%) of the Daptomycin group (P = 0.17).

124 t bacteremia were significantly lower in the daptomycin group compared to the vancomycin group (3.5%

125 In the daptomycin group, all patients received <72 hours of van

126 3 patients, 2 of which were in the combined Daptomycin group.

127 ncomycin arm and $110,920 in the combination Daptomycin group; however, no statistical significance w

128 Daptomycin has become a front-line antibiotic for multid

129 The lipopeptide antimicrobial daptomycin has in vitro bactericidal activity against VR

130 solates from patients who had never received daptomycin, higher daptomycin MICs tracked with increase

131 78; 95% CI, .55-.90; P = .012) and high-dose daptomycin (HR, 0.70; 95% CI, .41-.84; P = .006) were as

132 iously failed with vancomycin in 9 patients, daptomycin in 2, and sequential antibiotics in 5.

133 reus isolates, and two major errors (ME) for daptomycin in an S. aureus and a Staphylococcus epidermi

134 Two VMEs were observed for daptomycin in isolates of E. faecalis and 2 ME, 1 for hi

135 Compared with vancomycin, the usage of daptomycin in patients was not significantly associated

136 ferring increased tolerance of linezolid and daptomycin in patients who were treated with these antib

137 We report here our experience with high-dose daptomycin in the treatment of 25 cases of CIED endocard

138 safety of vancomycin, compared with that of daptomycin, in the treatment of MRSA BSIs with a high va

139 ltered membrane curvature, we confirmed that daptomycin inhibits cell wall synthesis.

140 Daptomycin is a bactericidal antibiotic of last resort f

141 Daptomycin is a calcium-dependent cyclic lipodepsipeptid

142 Daptomycin is a highly efficient last-resort antibiotic

143 Daptomycin is a lipopeptide antibiotic that is used clin

144 Daptomycin is a lipopeptide antibiotic used clinically f

145 Daptomycin is a lipopeptide with bactericidal activity t

146 y have proposed that calcium ions binding to daptomycin is a precondition for membrane interaction.

147 Daptomycin is an acidic lipopeptide antibiotic that, in

148 Daptomycin is an extensively used anti-staphylococcal ag

149 Because the mechanism of action of daptomycin is calcium-dependent depolarization of the ce

150 ium in a hospital system where resistance to daptomycin is evolving despite standard interventions.

151 The combination of meropenem plus daptomycin is more effective than ceftazidime as empiric

152 Daptomycin is one of the few treatment options for infec

153 Use of an empiric fixed dose of 750 mg of daptomycin is predicted to achieve a comparable PTA with

154 Daptomycin (IV) should be considered in patients with MR

155 daptomycin, with significant regrowth in the daptomycin killing assay compared to the treatment-naive

156 cal importance, the exact mechanism by which daptomycin kills bacteria is not fully understood.

157 cent lipid probes, we showed that binding of daptomycin led to a drastic rearrangement of fluid lipid

158 Finally, clustering of fluid lipids by daptomycin likely causes hydrophobic mismatches between

159 ver, alternative agents, such as telavancin, daptomycin, linezolid, ceftaroline, dalbavancin, oritava

160 SA isolates were susceptible to ceftaroline, daptomycin, linezolid, minocyline, tigecycline, rifampin

161 he isolates were susceptible to ceftaroline, daptomycin, linezolid, nitrofurantoin, quinupristin-dalf

162 Our experience suggests that high-dose daptomycin may be a safe therapeutic option in staphyloc

163 IC (P = 0.012) and a significant decrease in daptomycin MIC (P = 0.03) by year of study for Etest res

164 ance to human cathelicidin LL-37 killing and daptomycin MIC creep compared to non-USA600 MRSA.

165 and gdpD alleles of isolate R712 raised the daptomycin MIC for isolate S613 to 12 mug per milliliter

166 Strains with a daptomycin MIC of 1 mg/L exhibited significantly less ki

167 lecting strains with an intrinsically higher daptomycin MIC phenotype.

168 This study correlated the daptomycin MIC results obtained by Microscan and by Etes

169 A central laboratory performed standardized daptomycin MIC testing for all isolates.

170 ound between oxacillin MIC and vancomycin or daptomycin MIC.

171 difference in mortality with respect to the daptomycin MIC.

172 (MIC(50), 0.50 mug/mL; MIC(/90), 1 mug/mL), daptomycin (MIC(50), 0.25 mug/mL; MIC(90), 0.5 mug/mL),

173 tly improved in vitro activity compared with daptomycin (MIC90 0.5 vs 2 mug/mL) against Clostridium d

174 orse clinical outcomes than those exhibiting daptomycin MICs </=2 microg/mL.

175 study investigated "creep" in vancomycin and daptomycin MICs among methicillin-resistant Staphylococc

176 Vancomycin and daptomycin MICs from 161 isolates of methicillin-resista

177 In a multivariate logistic regression model, daptomycin MICs of 3-4 microg/mL (odds ratio [OR], 4.7 [

178 Daptomycin MICs of 3-4 microg/mL in the initial E. faeci

179 hat patients with E. faecium BSIs exhibiting daptomycin MICs of 3-4 microg/mL treated with daptomycin

180 s were infected with isolates that exhibited daptomycin MICs of 3-4 microg/mL.

181 ts who had never received daptomycin, higher daptomycin MICs tracked with increased resistance to kil

182 Daptomycin MICs were 1 to 2 log2 concentrations higher b

183 The daptomycin MICs were also significantly higher in the BB

184 vitro was the strongest predictor of higher daptomycin MICs within the daptomycin-susceptible range.

185 The reproducibility of vancomycin and daptomycin MICs, measured by broth microdilution (BMD) a

186 The daptomycin minimum inhibitory concentration (MIC) was 4

187 eviously showed that E. faecium strains with daptomycin minimum inhibitory concentrations (MICs) in t

188 Daptomycin minimum inhibitory concentrations (MICs) were

189 currence compared with patients treated with daptomycin monotherapy after adjusting for confounding v

190 Daptomycin monotherapy should be used cautiously against

191 Of 114 patients who received daptomycin monotherapy, 67 (58.8%) were alive at 30 days

192 patients were included (linezolid, n = 319; daptomycin, n = 325).

193 o membranes containing phosphatidylglycerol, daptomycin no longer forms pores or translocates to the

194 ent in relation to vancomycin resistance and daptomycin nonsusceptibility, respectively.

195 es in the context of cell-surface charge and daptomycin nonsusceptibility.

196 wo isolates were vancomycin intermediate and daptomycin nonsusceptible, and two isolates had reduced

197 inezolid-resistant Enterococcus (n = 5), and daptomycin-nonsusceptible Enterococcus faecalis (n = 6).

198 t vancomycin and results in activity against daptomycin-nonsusceptible organisms.

199 int mutation within mprF was observed in the daptomycin-nonsusceptible strain.

200 account for previously described effects of daptomycin on cell wall morphology and septation.

201 a LiaR-regulated protein, LiaX, that senses daptomycin or AMPs and triggers protective CM remodeling

202 Of patients treated with daptomycin or vancomycin, 29 (58%) and 51 (51%), respect

203 ncomycin patients and 9 (9.68%)/1 (1.08%) of Daptomycin patients, respectively (P < 0.02 and P = 1.00

204 ications in membrane structure that impaired daptomycin penetration and membrane disruption.

205 ose (aHR, 2.52; 95% CI, 1.27-5.00; P = .008) daptomycin persisted.

206 L and BODIPY FL-vancomycin), suggesting that daptomycin plays a direct role in these events.

207 vasive MRSA infections.Patients treated with daptomycin plus a beta-lactam for MRSA bloodstream infec

208 standard therapy (intravenous vancomycin or daptomycin) plus an antistaphylococcal beta-lactam (intr

209 significantly increased susceptibilities to daptomycin, polymyxin B, and two prototypical HD-CAPs (h

210 ollective findings lead us to propose that a daptomycin pore consists of two aligned tetramers in opp

211 This shift may have had a greater effect on daptomycin prescribing (-160 DOT/1000 patient-days; 95%

212 nd infection and perhaps, in turn, decreased daptomycin prescribing.

213 infection compared with adding supplemental Daptomycin prophylaxis.

214 Daptomycin protein binding was determined by equilibrium

215 biotic' to disable systemically-administered daptomycin reaching the gut.

216 tration-time profiles were simulated for two daptomycin regimens (8 mg/kg every 48 hrs and 4 mg/kg ev

217 While resistance to linezolid and daptomycin remains low overall, point mutations leading

218 Emergence of daptomycin resistance during therapy of serious enteroco

219 Daptomycin resistance in enterococci is often mediated b

220 In the daptomycin-exposed group, daptomycin resistance of E. faecium from the off-target

221 We performed a cohort study in which the daptomycin resistance of E. faecium isolated from rectal

222 ere was also greater phenotypic diversity in daptomycin resistance within daptomycin-exposed patients

223 gle cls2 point mutations were sufficient for daptomycin resistance, antibiotic treatment failure, and

224 , no association with persistent bacteremia, daptomycin resistance, or bacterial genotype was observe

225 frequently harbor mutations associated with daptomycin resistance.

226 here are multiple pathways to and factors in daptomycin resistance.

227 LiaX is surface exposed, and in daptomycin-resistant clinical strains, both LiaX and the

228 ramine therapy reduced the fecal shedding of daptomycin-resistant E. faecium by up to 80-fold.

229 The emergence and clinical significance of daptomycin-resistant enterococci and evolving microbiolo

230 at controls cell envelope homeostasis), from daptomycin-resistant Enterococcus faecalis not only reve

231 effect was also seen in a clinical strain of daptomycin-resistant Enterococcus faecium, using a murin

232 ompared with isolate S613, isolate R712--the daptomycin-resistant isolate--had changes in the structu

233 l (4 and 8 microg/ml(-1)) laboratory-derived daptomycin-resistant strains (strains CB1541 and CB1540

234 Treatment with daptomycin resulted in significantly improved outcomes,

235 Empirical therapy of intravenous daptomycin, rifampin and ceftriaxone was initiated.

236 gher risk of treatment failure compared with daptomycin (risk ratio [RR], 1.37; 95% confidence interv

237 chieved high peak concentrations to maximize daptomycin's concentration-dependent activity, and resul

238 were enrolled with measurements of 12 (2.2) daptomycin samples per patient.

239 ntimicrobial therapy, but before exposure to daptomycin, showed subtle physiological changes in respo

240 Daptomycin steady-state volume of distribution (0.23 +/-

241 oth mutants displayed reduced vancomycin and daptomycin susceptibility and phenotypic alterations (eg

242 Currently, there is debate over whether the daptomycin susceptibility breakpoint for enterococci (ie

243 stant Staphylococcus aureus (MRSA), in vitro daptomycin susceptibility could be influenced by exposur

244 5) defining the impact of VRE bacteremia and daptomycin susceptibility on patient outcomes.

245 Trends in vancomycin and daptomycin susceptibility were evaluated by using Etest

246 apy or both might have prevented the loss of daptomycin susceptibility.

247 All strains were daptomycin susceptible.

248 Among daptomycin-susceptible MRSA isolates from patients who h

249 edictor of higher daptomycin MICs within the daptomycin-susceptible range.

250 mg/kg for the treatment of VRE-BSI caused by daptomycin-susceptible VRE.

251 e was 1.5%-5.5% when the MIC was 4 mg/L (ie, daptomycin-susceptible) and 91.0%-97.9% when the MIC was

252 Combinations of CF-301 with vancomycin or daptomycin synergized in vitro and increased survival si

253 those of other methods, whereas the MICs for daptomycin testing were comparable.

254 54145 is a lipopeptide antibiotic related to daptomycin that permeabilizes bacterial cell membranes.

255 phase route to the synthesis of an analog of daptomycin that uses a reduced number of alpha-azido ami

256 oped a novel Caenorhabditis elegans model of daptomycin therapy and showed that disrupting LiaR-media

257 isolate predicted microbiological failure of daptomycin therapy, suggesting that modification in the

258 ral similarities with daptomycin, but unlike daptomycin they do not target bacterial membrane.

259 The stoichiometric ratio of daptomycin to calcium is 2:3.

260 The stoichiometric ratio of daptomycin to PG is approximately 1:1 if only the PG lip

261 Daptomycin transmembrane clearance (6.3 +/- 2.9 mL/min)

262 sharper declines in IL-10 than vancomycin or daptomycin -treated patients over 7 days.

263 ervational studies that assessed outcomes in daptomycin-treated enterococcal bacteremia.

264 ound a higher probability of survival in the daptomycin-treated group (P = .022).

265 lity was significantly lower among high-dose daptomycin-treated patients compared with other dosing s

266 rence of infection, was numerically lower in daptomycin-treated subjects (31% vs 17%; P = .084) and w

267 of 60-day mortality between vancomycin- and daptomycin-treated subjects found a higher probability o

268 mycin-treated subjects were compared with 59 daptomycin-treated subjects.

269 tive cholestyramine could enable therapeutic daptomycin treatment in the bloodstream, while preventin

270 istance to rapid return to sensitivity after daptomycin treatment stopped.

271 isolates, enhances S. aureus survival during daptomycin treatment.

272 Unadjusted carbapenem and daptomycin use decreased significantly.

273 ts infectious diseases consultation to guide daptomycin use for the SDD category.

274 istance to last resort drugs, vancomycin and daptomycin, using a novel, single cell, nanoscale techni

275 lyco-/lipopeptide (n=35), i.e. vancomycin or daptomycin (VAN/DAP).

276 ining strains were susceptible to linezolid, daptomycin, vancomycin, and teicoplanin.

277 stematically evaluated 5 methods for testing daptomycin versus 48 Enterococcus faecalis, 51 Enterococ

278 m of our study was to compare meropenem plus daptomycin versus ceftazidime in the treatment of nosoco

279 s is the first matched study comparing early daptomycin versus vancomycin for the treatment of MRSAB

280 atment failure, via blinded adjudication, in daptomycin- vs vancomycin-treated subjects and the inter

281 Daptomycin was administered for a median of 20 days (ran

282 total of 7.7 +/- 0.6 mg/kg (mean +/- sd) of daptomycin was administered, resulting in an observed pe

283 The results demonstrated that daptomycin was associated with a better outcome compared

284 High-dose daptomycin was associated with improved survival and mic

285 y of 246 patients with S. aureus bacteremia, daptomycin was not inferior to vancomycin or an antistap

286 o serious adverse event related to high-dose daptomycin was observed and no patient required disconti

287 The combination of meropenem plus daptomycin was significantly more effective than ceftazi

288 Once daptomycin was started, the population became more heter

289 dose (HR, 2.66; 95% CI, 1.33-3.92; P = .003) daptomycin were associated with poorer survival.

290 py, and susceptibilities to tPMP, hNP-1, and daptomycin were compared using univariate and multivaria

291 o previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infect

292 Frontline MRSA treatments, vancomycin and daptomycin, were unable to eradicate MRSA biofilms or no

293 lele from isolate R712 quadrupled the MIC of daptomycin, whereas replacement of the gdpD allele had n

294 ient defence mechanism that protects against daptomycin, which can be compromised by Agr-triggered to

295 Our results support a mechanism for daptomycin with a primary effect on cell membranes that

296 careful circular dichroism (CD) analyses of daptomycin with Ca(2+) and PG-containing membranes, we f

297 study compared the clinical effectiveness of daptomycin with that of vancomycin for the treatment of

298 opy to directly visualize the interaction of daptomycin with the model Gram-positive bacterium Bacill

299 Effect of vancomycin or daptomycin with vs without an antistaphylococcal beta-la

300 subtle physiological changes in response to daptomycin, with significant regrowth in the daptomycin